Tickers — V

49 tickers
Ranks this page's recent reports by score.
Victoria's Secret & Co.
VSXY·Consumer Discretionary
B ★★★Hold
Current$74.54
Target$82.28
Return+10.4%
Sep 15, 2026

Victoria's Secret is executing a credible brand-and-margin turnaround with rising earnings and cash generation, but meaningful leverage and a substantial valuation premium to apparel peers limit the margin of safety after the stock's sharp rerating.

Score
72
Veeva Systems Inc.
VEEV·Healthcare
S ★★★★★Strong Buy
Current$293.88
Target$350.00
Return+19.1%
Aug 29, 2026

Veeva Systems is the hyper-profitable tollbooth of the life sciences cloud, trading at a rare discount on transition fears, though investors must watch execution risk in its large migration from Salesforce to its own Vault CRM platform.

Score
96
Vipshop Holdings Limited
VIPS·Consumer Discretionary
B ★★★Hold
Current$14.02
Target$19.15
Return+36.6%
Aug 28, 2026

Vipshop offers a fortress balance sheet and aggressive capital returns at a highly distressed valuation, but remains heavily weighed down by shrinking active user counts and tightening operating margins caused by a stagnant Chinese retail environment.

Score
80
Vericel Corporation
VCEL·Healthcare
B ★★★Hold
Current$44.26
Target$57.20
Return+29.2%
Aug 25, 2026

Vericel operates a monopolistic, high-margin autologous cell therapy engine transitioning into a cash-generating powerhouse, though its premium valuation requires flawless execution in the MACI Arthro rollout to prevent multiple compression.

Score
76
V2X, Inc.
VVX·Industrials
A ★★★★Buy
Current$78.50
Target$102.00
Return+29.9%
Aug 25, 2026

V2X is an entrenched, fast-growing defense prime at a deep discount, with room for multiple expansion as it deleverages, though investors must tolerate near-term volatility from structural accounts receivable timing delays.

Score
87
Vera Therapeutics, Inc.
VERA·Healthcare
C ★★Sell
Current$32.28
Aug 24, 2026

Vera Therapeutics possesses a highly differentiated, best-in-class dual-inhibitor with fresh FDA approval for a lucrative rare disease market, but its extreme cash burn, impending dilution risk, and entry into an intensely crowded competitive landscape mandate a highly cautious approach until commercial traction is proven.

Score
60
Versigent PLC
VGNT·Consumer Discretionary
A ★★★★Buy
Current$49.26
Target$73.60
Return+49.4%
Aug 23, 2026

Versigent is a deeply entrenched, cash-gushing tollbooth for global vehicle electrification trading at a drastically misunderstood distressed valuation, though investors must stomach the inevitable quarter-to-quarter volatility driven by copper prices and cyclical global auto production.

Score
94
Marriott Vacations Worldwide Corporation
VAC·Consumer Discretionary
B ★★★Hold
Current$112.55
Target$128.02
Return+13.7%
Aug 22, 2026

Marriott Vacations offers a highly profitable, cash-generative turnaround play driven by a massive $200 million margin modernization program, though investors must cautiously navigate the overarching threat of consumer credit fragility and a heavily indebted balance sheet.

Score
82
Viking Holdings Ltd
VIK·Consumer Discretionary
B ★★★Hold
Current$97.99
Target$118.45
Return+20.9%
Aug 21, 2026

Viking is the undisputed, cash-gushing titan of luxury experiential cruising with near-perfect revenue visibility into 2027, but investors must exercise strict discipline regarding an extended valuation multiple that prices in flawless execution amid unpredictable European river climate disruptions.

Score
80
Versant Media Group, Inc.
VSNT·Communication Services
B ★★★Hold
Current$39.65
Target$46.40
Return+17.0%
Aug 17, 2026

Versant generates immense free cash flow and commands premier news and sports brands, but remains aggressively discounted by the market due to the inescapable secular decline of its legacy pay-TV distribution engine.

Score
80
Valvoline Inc.
VVV·Consumer Discretionary
A ★★★★Buy
Current$34.19
Target$39.82
Return+16.5%
Aug 17, 2026

Valvoline is the undisputed, highly scalable tollbooth of the non-discretionary automotive maintenance sector, trading at an absurdly low implied growth rate, though investors must remain vigilant regarding its elevated debt load and backend IT integration risks.

Score
85